NAD Recommends Bausch + Lomb Modify, Discontinue Certain Claims Made in Advertorial; Claims Challenged by Alcon Laboratories

New York, NY – April 10, 2013 – The National Advertising Division has recommended that Bausch + Lomb Inc., modify or discontinue certain claims made in an advertorial context that refer to Alcon Laboratories, Inc.’s OPTI-FREE RepleniSH contact lens solution.

NAD is an investigative unit of the advertising industry’s system of self-regulation. It is administered by the Council of Better Business Bureaus.

The advertorial, challenged by Alcon, alerted eye-care practitioners to an increase in reports of infiltrative keratitis, a condition that can affect the vision and comfort of contact lens wearers.

Titled “Infiltrative Keratitis and Gram-Negative Bacterial Resistance to PQ-Aldox Lens Care Products,” the advertorial appeared in publications directed to eye-care professionals.

Claims at issue included:

  • “Contact lens associated infiltrative keratitis (“CLAIK”) has been reported at higher rates in particular with polyquaternium (PQ)-Aldox (myristamidopropyl dimethylamine) based Multi-Purpose Solutions (MPS).”
  • “Notably, CLAIK has repeatedly been associated with one PQ-Aldox MPS, OPTI-FREE RepleniSH in independent studies. In one report, this solution was being used in 71% of CLAIK cases.”

NAD also examined whether the advertising at issue implied that Alcon’s OPTI-FREE RepleniSH contact lens solution poses the risk of or causes corneal infiltrative events or CIEs.

NAD noted in its decision that advertisers are responsible for all messages conveyed by their advertising, not only the messages they intended to communicate.

In this case, NAD determined that the challenged advertorial conveyed the messages that consumers who wear silicone hydrogel lenses and use Opti-Free RepleniSH are substantially more likely to experience, or are at a greater risk for, CLAIK than other contact lens solutions; and that eye care practitioners should switch their patients to the advertiser’s Biotrue solution which has been shown to reduce their patients’ risk for CLAIK.

NAD further determined that the advertiser’s evidence did not support any of these messages. NAD noted in its decision that none of the studies offered as evidence found that patients were at a greater risk for CLAIK due to the use of Opti-Free RepleniSH alone, nor did the studies advise practitioners to switch their patients to a non-PQ-Aldox MPS because such a change had been shown to reduce the risk of CLAIK.

NAD recognizes that emerging science is important to eye care professionals and that so long as it is truthful and accurate, it is information that the advertiser should be free to disseminate. However, it recommended that the advertiser modify its advertorial to:

  • Avoid communicating that consumers who wear silicone hydrogel lenses and use Opti-Free Replenish are substantially more likely to experience, or are at a greater risk for, CLAIK than other contact lens solutions
  • Refer to PQ-Aldox MPS, rather than the brand name product, Opti-Free RepleniSH.
  • Discontinue its recommendation that professionals switch their patients from Opti-Free RepleniSH to Biotrue to reduce their risk of CLAIK and/or CIEs.

Bausch + Lomb, in its advertiser’s statement, said that while the company respectfully disagrees with NAD’s findings concerning the net impressions of the advertorial, it “appreciates NAD’s recommendations on how to avoid any future confusion about the intended message. Bausch + Lomb will seek ways in which to incorporate this helpful guidance in any future advertising or promotional communications about this emerging field of study.”

Latest Decisions

Decision

Privacy Watchdog Brings Healthcare Company into Compliance with Ad Privacy Best Practices

McLean, VA – December 1, 2020 – BBB National Programs’ data privacy watchdog, the Digital Advertising Accountability Program (DAAP), today released the result of a new data privacy case for the healthcare and medical devices company Abbott, who worked with DAAP to bring more than 60 of its websites into compliance with the Digital...
Read Decision
Decision

NARB Recommends that Young Living Essential Oils Discontinue “Therapeutic Grade” and Health and Wellness Benefit Claims

New York, NY – November 24, 2020 – A panel of the National Advertising Review Board (NARB), the appellate advertising law body of BBB National Programs, has recommended that Young Living Essential Oils, LC (Young Living) discontinue “therapeutic grade” claims for its “essential oils,” as...
Read Decision
Decision

Two Fast-Track SWIFT Cases Close in October, One Voluntary Discontinuation of Claim and One Administrative Closure

New York, NY – November 23, 2020 – The National Advertising Division (NAD) closed two Fast-Track SWIFT cases in October, one a challenge brought by DISH Network Wireless against T-Mobile, and the other challenge brought by one maker of personal care products versus another, which was closed by consent of the parties.
Read Decision
Decision

NAD Finds AT&T’s “Best Possible” Blog Post Claims Supported

New York, NY – November 19, 2020 – The National Advertising Division (NAD) determined that AT&T Services, Inc. provided a reasonable basis for its self-referential “best possible” claims made in two blog posts on AT&T’s website. 

Read Decision